Argenx - About the company
Argenx is a deadpooled company based in London (United Kingdom), founded in 2017. It operates as a Develops therapeutic antibodies for cancer. The company has 2368 active competitors, including 606 funded and 445 that have exited. Its top competitors include companies like Abcellera Biologics, Zymeworks and Harbour BioMed.
Company Details
Argenx discovers, designs and develops innovative antibody therapeutics for treatments of cancer and autoimmune diseases and for its partners. The company uses llama immune system with antibody engineering called SIMPLE Antibody™ Platform to produce humanized antibodies. Currently, its ARGX-113 for autoimmune disease in Phase II trial, and the following candidates ARGX-110, ARGX-111, ARGX-115 are in Phase II, Phase I, and Phase I respectively for Oncology.
- Website
- argenxpharma.org
- Email ID
- *****@argenxpharma.org
- Phone Number
- +44 **********
Key Metrics
Founded Year
2017
Location
London, United Kingdom
Stage
Deadpooled
Ranked
3038th among 3198 competitors
Similar Companies
Sign up to download Argenx's company profile
Argenx's funding and investors
Argenx has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Argenx's Competitors and alternates
Top competitors of Argenx include Abcellera Biologics, Zymeworks and Harbour BioMed. Here is the list of Top 10 competitors of Argenx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 76/100 | |
2nd | Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 71/100 | ||
3rd |  Harbour BioMed 2016, Shanghai (China), Public | Developer of antibody therapeutics in immunology and oncology disease | $313M | 71/100 | |
4th | Synthego 2012, Redwood City (United States), Acquired | Developer of CRISPR-engineered cell and gene therapies | $460M | 71/100 | |
5th | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
6th | _1556184640480.png?devicePixelRatio=2&height=30&width=30){kind=logo} TScan Therapeutics 1995, Boston (United States), Public | Developer of T cell therapies to harness the immune system against cancer | $180M | 70/100 | |
7th | ABL Bio 2016, Seongnam-si (South Korea), Public | Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 67/100 | |
8th | Xilio Therapeutics 2016, Waltham (United States), Public | Developer of immunotherapies for the treatment of cancer | $233M | 67/100 | |
9th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
10th | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
3038th | Argenx 2017, London (United Kingdom), Deadpooled | Develops therapeutic antibodies for cancer | - | - | 15/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Argenx's competitors? Click here to see the top ones
Argenx's Investments and acquisitions
Argenx has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Argenx
Explore our recently published companies
- Yutaka-Giken - Japan based, Unfunded company
- Newspace - Unfunded company
- RiCapital - United States based, 2020 founded, Unfunded company
- campobiosciences - Unfunded company
- Tomei Powered - Japan based, 1968 founded, Unfunded company
- Sansho Co., Ltd. - Japan based, Unfunded company
